EU/3/05/263: Orphan designation for the treatment of severe closed traumatic brain injury

Dimethyl sulfoxide

Table of contents

Overview

On 3 March 2005, orphan designation (EU/3/05/263) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for dimethyl sulfoxide for the treatment of severe closed traumatic brain injury.

In February 2022, the sponsor’s address was updated and the name was changed from AOP Orphan Pharmaceuticals AG to Aop Orphan Pharmaceuticals GmbH.

Key facts

Active substance
Dimethyl sulfoxide
Intended use
Treatment of severe closed traumatic brain injury
Orphan designation status
Positive
EU designation number
EU/3/05/263
Date of designation
03/03/2005
Sponsor

Aop Orphan Pharmaceuticals GmbH
Leopold-Ungar-Platz 2
Doebling
1190 Vienna
Austria
E-mail: office@aoporphan.at

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
1 rating
1 rating